AstraZeneca: new data show Tagrisso advantage.
(CercleFinance.com) - AstraZeneca said on Monday that new data showed an advantage for patients with EGFR-mutated non-small cell lung cancer and metastases patients treated with its Tagrisso drug compared with standard treatment.
A phase III trial demonstrated a 52% risk reduction of central nervous system disease progression, or death, in patients treated with Tagrisso compared to current standard-of-care EGFR tyrosine kinase inhibitor.
The trial's full results were published online today in the New England Journal of Medicine.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
A phase III trial demonstrated a 52% risk reduction of central nervous system disease progression, or death, in patients treated with Tagrisso compared to current standard-of-care EGFR tyrosine kinase inhibitor.
The trial's full results were published online today in the New England Journal of Medicine.
Copyright (c) 2017 CercleFinance.com. All rights reserved.